Jeffrey Hansen
Psychiatry · Vancouver, WANPI 1356410419
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,155,444 of the $2,759,763 with a category attached, or 78.1%. 26 manufacturers reported payments, led by AbbVie at 31.1% of the total. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,790 payments — averaging $728.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$858K
- Neurocrine Biosciences, Inc.$547K
- Johnson & Johnson$320K
- Otsuka America Pharmaceutical, Inc.$279K
- Teva Pharmaceuticals USA, Inc.$272K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$170K
- plus $315K from 20 others
What the payments were for
- Consulting fees$156,2906%
- Speaking & faculty fees$2,155,44478%
- Travel & lodging$384,26614%
- Food & beverage$63,4672%
- Education$2950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 1,228 | $858,318 |
| Neurocrine Biosciences, Inc. | 586 | $546,755 |
| Johnson & Johnson | 394 | $319,595 |
| Otsuka America Pharmaceutical, Inc. | 369 | $278,507 |
| Teva Pharmaceuticals USA, Inc. | 346 | $271,552 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 239 | $169,634 |
| Alkermes, Inc. | 139 | $93,750 |
| Axsome Therapeutics, Inc. | 142 | $82,812 |
| E.r. Squibb & Sons, L.L.C. | 57 | $39,754 |
| Jazz Pharmaceuticals Inc. | 50 | $33,057 |
| Supernus Pharmaceuticals, Inc. | 81 | $23,866 |
| Vanda Pharmaceuticals Inc. | 55 | $19,494 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $11,950 |
| Sunovion Pharmaceuticals Inc. | 8 | $3,345 |
| Eisai Inc. | 3 | $2,327 |
| Corium, LLC | 18 | $2,327 |
| Merck | 8 | $1,702 |
| Lundbeck LLC | 18 | $432 |
| Ironshore Pharmaceuticals Inc. | 13 | $198 |
| Janssen Scientific Affairs, LLC | 2 | $145 |
| Noven Therapeutics, LLC | 3 | $72 |
| Vertical Pharmaceuticals, LLC | 3 | $69 |
| Collegium Pharmaceutical, Inc. | 1 | $29 |
| Sage Therapeutics, LLC | 1 | $28 |
| Bausch Health US, LLC | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,759,763 in reported general payments places this provider in the 95th percentile of 576 psychiatry providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 35 | $273,014 |
| AustedoDeutetrabenazine | 12 | $127,548 |
| VraylarCariprazine Hcl | 27 | $37,647 |
| Abilify MaintenaAripiprazole | 12 | $32,607 |
| TrintellixVortioxetine Hydrobromide | 31 | $26,459 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $11,019 |
| Lisdexamfetamine Dimesylate | 23 | $7,716 |
| Aripiprazole | 95 | $3,767 |
| Clozapine | 52 | $2,799 |
| Divalproex Sodium | 22 | $1,821 |
| Escitalopram Oxalate | 127 | $1,344 |
| Bupropion XlBupropion Hcl | 41 | $1,234 |
| Methylphenidate Hcl | 18 | $1,029 |
| Lamotrigine | 56 | $1,016 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $546,755 | $273,01435 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $271,552 | $127,54812 claims |
| AbbVieVraylar | $858,318 | $37,64727 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $278,507 | $32,60712 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $11,950 | $26,45931 claims |
| Axsome Therapeutics, Inc.Auvelity | $82,812 | $11,01911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 psychiatry providers in Washington.
Other psychiatry in Vancouver
- Elia Gonzalez-RodriguezVancouver$4K
- Jerald BlockVancouver$4K
- Michael DomashVancouver$3K
- George MosesVancouver$1K
- Chester RobachinskiSeattle$1.1M
- Larry BornsteinEverett$663K
- Matthew BogoyasYakima$500K
- Pablo ProanoSeattle$112K
- David DunnerMercer Island$79K
- Jesse McClellandSeattle$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.